The task ahead of Vertex now is to migrate patients already on Trikafta to the new drug. That is supported by data from the ...

The US Food and Drug Administration (USFDA) has revoked the emergency use authorisation for four Covid-19 antibody-based ...

The accelerated approval is part of the FDA’s Project FrontRunner, aimed at advancing cancer drug development.

US pharma giant Pfizer on Friday revealed that the US Food and Drug Administration (FDA) has approved its Braftovi ...

Pfizer’s BRAFTOVI combination regimen receives US FDA approval for treatment of metastatic colorectal cancer: New York Monday, December 23, 2024, 10:00 Hrs [IST] Pfizer Inc anno ...

Pfizer's efficiency at spending on R&D and Capex is set to look much better. Click here to see why PFE stock is a Buy.

We recently published a list of the 8 Best Dividend Leaders to Buy According to Wall Street Analysts. In this article, we are ...

Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has approved BRAFTOVI® (encorafenib) in combination with ...

Pfizer Inc. (PFE) said that the U.S. Food and Drug Administration has approved BRAFTOVI (encorafenib) in combination with cetuximab ...

Intelligent Living Application Group Inc. (the "Company" or "Intelligent Living"), a premium lockset manufacturer and distributor headquartered in Hong Kong, today announced its unaudited financial ...

Pfizer said Friday that the Food and Drug Administration approved its treatment for patients with metastatic colorectal cancer.